Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Numerate, a biotechnology company, has received a Phase I grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.
Subscribe to our email newsletter
The small business technology transfer (STTR) award will be used to support a research collaboration between Numerate and the laboratory of Chaitan Khosla, the Wells Rauser and Harold Petiprin professor of chemical engineering and chemistry at Stanford University.
John Griffin, chief scientific officer of Numerate, said: “This National Institutes of Health (NIH) Phase I STTR award validates the attractiveness of Numerate’s drug engineering process for the design of new small molecule drugs.
“In addition, it recognizes the potential of transglutaminase 2 inhibitors for the treatment of celiac sprue. Professor Khosla is a leader in celiac disease research, and we are pleased to have the support of the NIH in our collaboration with him and his laboratory.”